iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will unveil the latest generation of ProFound AI® for 2D Mammography at the Journées Francophones de Radiologie (JFR) meeting in Paris, Friday through Monday.
In addition, the company, based in Nashua, New Hampshire, will showcase its most recent technological advancements, including the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT) and ProFound AI® Risk, in its booth.
"The European launch of our third generation of ProFound AI for 2D Mammography demonstrates iCAD’s steadfast commitment to improving breast cancer detection for all women worldwide," said President Stacey Stevens.
"By using this leading-edge technology, both general and breast radiologists can potentially improve their accuracy and performance, which may in turn have a positive impact on women and the healthcare system overall."
In addition, the new version of ProFound AI Risk will also be available for demonstration at the iCAD booth at JFR. This solution, now available for tomosynthesis, provides an accurate estimate of the risk of short-term breast cancer, which is truly personalized for each woman.
Regular, age-based mammography screening reduces breast cancer mortality by approximately 20%, but screening mammography can still miss 20 to 40% of breast cancers. Many of these cancers are diagnosed as interval breast cancers, defined as those that emerge after a normal mammogram but before the woman’s next scheduled screening.
ICAD shares gave back a penny to $10.46.
